Cimeio Therapeutics, a key player in the field of innovative therapeutics, has made a significant announcement regarding a preclinical research collaboration with the University of Pennsylvania.
This collaboration, spearheaded by Saar Gill, M.D., Ph.D., an esteemed associate professor of medicine and a researcher at the University’s Center for Cellular Immunotherapies, aims to delve into the realm of universal immunotherapy.
The objective is to create a potential treatment modality for various types of blood and bone marrow cancers. The collaboration capitalizes on the unique strengths of both entities, leveraging Cimeio Therapeutics’ proprietary epitope-editing and CD45-targeting technologies in tandem with Penn Medicine’s epitope-editing and CAR T cell technology.
The ultimate goal is to design a revolutionary CD45-targeting CAR T cell therapy coupled with epitope-edited hematopoietic stem cells (HSCs). CD45, being prominently present on the surface of a wide array of blood cells, is a pivotal receptor that holds promise for the development of a universal CAR T cell therapy tailored for blood cancers.
Recent breakthroughs in epitope editing have shown promise in effectively editing CD45, a receptor ubiquitously expressed on the surface of both healthy HSCs and numerous blood and bone marrow cancers.
This collaboration builds upon the research and findings that have demonstrated the potential to shield healthy HSCs while making malignant cells susceptible to a CD45-targeting therapy, presenting a promising avenue for drug development. In addition to this groundbreaking research, Cimeio Therapeutics is advancing its efforts in the field by also working on the development of a CD45-directed antibody-drug conjugate.
The company has a strategic vision to develop this therapy utilizing CD45 epitope shielded cells, not only for blood cancers but also for autoimmune diseases and various other indications.
